113 results
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
; the profile and potential application of obe- cel in additional disease settings; the future clinical development, efficacy, safety and therapeutic potential … do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; and possible safety
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Obe-cel … and safety. The trial enrolled over 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
1 Apr 24
Departure of Directors or Certain Officers
7:06am
, and possible safety and efficacy concerns. For a discussion of other risks and uncertainties, and other important factors, any of which could cause
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
regulatory approval for and launch a product commercially.
Table of contents
Adverse side effects or other safety risks associated with our product … trials of any of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the Food and Drug Administration (“FDA
10-K
EX-10.12
ylzkiy7 km
21 Mar 24
Annual report
4:55pm
8-K/A
EX-99.1
4cl3 ibm6x8k
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.1
kjbb xievnozebc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.2
qy7jcxfxyyimg
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
7i3gqjnt 30jv
13 Feb 24
Regulation FD Disclosure
4:06pm
8-K
m2x3byse ar4u
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
065 lnqkdjhsd8caeha
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
lc5wy
26 Jan 24
Regulation FD Disclosure
1:02pm
8-K
EX-99.1
epz aufyp
10 Jan 24
Departure of Directors or Certain Officers
3:12pm
8-K
EX-99.1
0h7jdl
22 Dec 23
Departure of Directors or Certain Officers
8:24am
8-K
EX-99.1
z56elf2jrgf7 b06fw
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.2
ap1jfgumhbkfgrj zr
11 Dec 23
Regulation FD Disclosure
8:31am
8-K
EX-99.1
7d07r9 yyor
27 Nov 23
Regulation FD Disclosure
7:07am
10-Q
2v3y0jv
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-10.1
75vcy1tlqr
9 Nov 23
Quarterly report
4:18pm